Chimerix is selling global rights to smallpox drug Tembexa, the biotech’s only FDA-approved product, as a way to fund clinical development of a therapy in pivotal testing for a rare type of brain cancer. The deal marks Chimerix’s nearly complete departure from the antiviral work that defined the company for most of its history.
The development of the drug, DSTAT, is based on preclinical research indicating it can inhibit the inflammatory cytokines involved in the cytokine storms that cause much of the morbidity and mortality in Covid-19, as well as addressing the coagulation issues resulting in young patients having strokes.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The unfolding effort to contain the Ebola virus in the U.S. is revitalizing the issue of giving people access to experimental medication and the ethical wrangling involved in making those decisions, referred to as Compassionate Use or Right to Try. Cue a timely talk by Kenneth Moch, the former CEO of biotechnology company Chimerix, which […]
North Carolina biotechnology company Chimerix reported positive phase 2 results for a broad spectrum antiviral agent expected to have applications fighting infections faced by bone marrow transplant patients. Chimerix now plans to start phase 3 clinical trials on CMX001 later this year. The company is studying the compound for the prevention of cytomegalovirus diseases, or […]
Vaccine developer Chimerix has added life sciences industry veteran Timothy Trost to its management team. Durham, North Carolina-based Chimerix has named Trost to the newly created position of senior vice president, chief financial officer. Before coming to Chimerix, Trost was CFO of Argos Therapeutics in Research Triangle Park. Trost’s 30-year career in the industry includes […]
Release of smallpox as a bioterrorism weapon is a possibility that antiviral company Chimerix has been awarded $81 million to combat. The federal contract will be used to develop the Durham, North Carolina company's antiviral drug candidate into a smallpox treatment.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Antiviral therapies pharmaceutical company Chimerix has raised $45 million that it will apply toward further clinical development of two compounds, one of which could be used as a defense against biological attacks. The Durham, North Carolina-based company is developing another compound for infections associated with HIV.